Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus SBRT as neoadjuvant therapy for resectable hepatocellular carcinoma
ChiCTR2600116934Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of sintilimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Shandong First Medical University. Primary endpoints: 3-year recurrence rate, Disease control rate and 2 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600116934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116934.